A randomised phase III trial of high dose palliative radiotherapy (HDPRT) versus concurrent chemotherapy and HDPRT (C-HDPRT) in patients with good performance status, locally advanced/small volume metastatic NSCLC not suitable for radical chemo-radiotherapy.

The purpose of this study is to investigate whether adding chemotherapy to a short (less than six weeks) course of radiotherapy results in a greater improvement in symptoms and overall wellbeing (quality of life) compared with using a short course of radiotherapy alone in patients with Non-Small Cell Lung Cancer (NSCLC) who cannot be treated with surgery or a long (six weeks or longer) course of radiotherapy and chemotherapy.

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Final Accrual

76

Trial Chairperson

Associate Professor Margot Lehman, Princess Alexandra Hospital, QLD

Clinical Trial Registration

Related Post

David, Jasmine and Susan Goode, re Kokoda Challenge to support TROG Cancer Research
27 May, 2025

Intrepid trekkers to take on Kokoda Challenge for TROG

LATEST NEWS: 27 May 2025 A team of five

Clinical Trials Day 2025 stand at Calvary Mater Newcastle
27 May, 2025

Clinical Trials Day celebrations help spread the work about TROG’s work

LATEST NEWS: 27 MAY 2025 TROG members and staff